Gabriele Di Gesaro1*, Federica Bellini2, Antonino Granata3, Giovanni Gentile4, Sergio Sciacca5 and Francesco Clemenza1
1Department for the Study and Treatment of Cardiothoracic Diseases and for Cardiothoracic Transplants, Cardiology Unit, IRCCS-ISMETT, Italy
2Department of Internal Medicine, National Relevance and High Specialization Hospital Trust ARNAS Civico, Di Cristina, Italy
3Department of Diagnostic and Therapeutic Services, Endoscopy Service, IRCCS-ISMETT, Italy
4Department of Diagnostic and Therapeutic Services, Radiology Unit, IRCCS-ISMETT, Italy
5Department of Study and Treatment of Cardiothoracic Diseases and for Cardiothoracic Transplants, Cardio Surgery Unit, IRCCS-ISMETT, Italy
The Left Ventricular Assist Devices (LVAD) is considered a good way to improve survival and quality of life in patients with end stage left ventricular failure compared to the optimal medical therapy alone. Long-term survival of patients receiving LVADs may be complicated by different cardiac (heart failure and arrhythmia) and extra-cardiac diseases: Bleeding, infections, and thrombosis, many of which could require different intervention. Endoventricular thrombolysis may have a pivotal role in LVAD thrombosis. The coexisting risk of angiodysplasia gastrointestinal bleeding, often elevated in patient with this type of non pulsatile ventricular assistance device should be considered by single case.
Left ventricular assist devices; Heart failure; HeartWare™; Thrombosis; Thrombolysis; Angiodysplasia
Di Gesaro G, Bellini F, Granata A, Gentile G, Sciacca S, Clemenza F. Angiodysplasia Coagulation and Intraventricular Thrombolysis in Patient with Left Ventricular Assist Device Thrombosis: The Combined Strategy of Management of this Rare Patient. Clin Surg. 2021; 6: 3386..